Specify a stock or a cryptocurrency in the search bar to get a summary
Cyclerion Therapeutics Inc
CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Riverview II, Cambridge, MA, United States, 02142
Analytics
WallStreet Target Price
4 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CYCN
Dividend Analytics CYCN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CYCN
Stock Valuation CYCN
Financials CYCN
Results | 2019 | Dynamics |